Abstract
Aim:
To investigate the effects of rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, on the expression of the phosphatase and tensin homologue deleted on chromosome 10 gene (PTEN) and cell growth in hepatocellular carcinoma cells, as well as the underlying mechanisms of these effects.
Methods:
RT-PCR and Western blotting analyses were performed to detect transcription and the expression of PTEN in Hep3B cells treated with rosiglitazone. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was used to evaluate cell growth. Flow cytometry, DNA fragmentation analysis, caspase enzymatic assay, and Hoechst 33258 staining were used to determine cell apoptosis. Furthermore, small interfering RNA was used to suppress PTEN expression.
Results:
Rosiglitazone increased the expression of PTEN in a dose-and time-dependent manner through the PPARγ-dependent signal transduction pathway. PTEN upregulation was concomitant with a decreased level of Akt phosphorylation, subsequently resulting in cell growth inhibition and apoptosis in Hep3B cells. PTEN knockdown dramatically blocked these effects of rosiglitazone. Moreover, the exposure of cells to rosiglitazone activated caspases-9 and -3 during apoptotic proceeding.
Conclusion:
Thus, upregulation of PTEN is involved in the inhibition of cell growth and the induction of cell apoptosis by rosiglitazone, suggesting that rosiglitazone may be useful in liver cancer therapy via apoptosis.
Similar content being viewed by others
Article PDF
References
Parkin DM . Global cancer statistics in the year 2000. Lancet Oncol, 2001; 2: 533–43.
Koeffler HP . Peroxisome proliferators-activated receptor gamma and cancers. Clin Cancer Res, 2003; 9: 1–9.
Meirhaeghe A, Tanck MW, Fajas L, Janot C, Helbecque N, Cottel D, et al. Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab, 2005; 85: 140–8.
Koeffler HP . Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res, 2003; 9: 1–9.
Wang T, Xu J, Yu X, Yang RC, Han ZC . Peroxisome proliferator-activated receptor gamma in malignant disease. Crit Rev Oncol Hematol, 2006; 58: 1–14.
Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator activated receptor gamma. J Pharmacol Exp Ther, 1998; 284: 751–9.
Kim KY, Kim SS, Cheon HG . Differential anti-proliferative actions of peroxisome proliferators-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol, 2006; 72: 530–40.
Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP . Redox regulation of PI3-kinase signalling via inactivation of PTEN. EMBO J, 2003; 22: 5501–10.
Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M . Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol, 2000; 20: 8969–82.
Zhang LN, Yu Q, He JY, Zha XL . Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biol, 2004; 262: 25–33.
Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH . Tumor suppressor and anti-inflammatory actions of PPARg agonists are mediated via upregulation of PTEN. Curr Biol, 2001; 11: 764–8.
Zhou BR, Gumenscheimer M, Freudenberg, M, Galanos C . A striking correlation between lethal activity and apoptotic DNA fragmentation of liver in response of D-galactosamine-sensitized mice to a non-lethal amount of lipopolysaccharide. Acta Pharmacol Sin, 2003; 24: 193–8.
Stoll V, Calleja V, Vassaux G, Downward J, Lemoine NR . Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut, 2005; 54: 109–16.
Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo J P, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer, 2005; 114: 242–8.
Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res, 2004; 64: 5232–6.
Vivanco I, Sawyers CL . The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer, 2002; 2: 489–501.
Testa JR, Bellacosa A . AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA, 2001; 98: 10 983–5.
Cantley LC . The phosphoinositide 3-kinase pathway. Science, 2002; 296: 1655–7.
Chan TO, Rittenhouse SE, Tsichlis PN . Akt/PKB and other D3 phosphoinositide-regula ted kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem, 1999; 68: 965–1014.
Maehama T, Dixon JE . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem, 1998; 273: 13 375–8.
Yim HW, Jong HS, Kim TY, Choi HH, Kim SG, Song SH, et al. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res, 2005; 65: 1952–60.
Okano H, Shiraki K, Inoue H, Yamanaka Y, Kawakita T, Saitou Y, et al. 15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferators-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest, 2003; 83: 1529–39.
Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C . Increased PTEN expression due to transcriptional activation of PPARgamma by lovastatin and rosiglitazone. Int J Cancer, 2006; 118: 2390–8.
Farrow B, Evers BM . Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun, 2003; 301: 50–3.
Han S, Roman J . Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther, 2006; 5: 430–7.
Chen WC, Lin MS, Bai X . Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity. Chin Med J (Engl), 2005; 118: 1477–81.
Chang HC, Tsai LH, Chuang LY, Hung WC . Role of Akt kinase in sphingosine-induced apoptosis in human hepatoma cells. J Cell Physiol, 2001; 188: 188–93.
Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T . Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology, 2003; 38: 756–68.
Yu J, Qiao L, Zimmermann L, Ebert M P, Zhang H, Lin W, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43: 134–43.
Bae MA, Song BJ . Critical role of c-Jun N-termial protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol, 2003; 63: 401–8.
Li M, Lee T W, Yim A P, Mok TS, Chen GG . Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol, 2006; 209: 428–38.
Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, et al. A ligand for peroxisome proliferators activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut, 2002; 50: 563–7.
Date M, Fukuchi K, Morita S, Takahashi H, Ohura K . 15-Deoxy-delta 12, 14-prostaglandin J2, a ligand for peroxisome proliferators-activated receptor-gamma, induces apoptosis in human hepatoma cells. Liver Int, 2003; 23: 460–6.
Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J . PTEN: a crucial mediator of mitochondria-dependent apoptosis. Apoptosis, 2006; 11: 197–207.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by the Foundation of Science and Technology Committee of Guangzhou City (No 2004Z2-E0132).
Rights and permissions
About this article
Cite this article
Cao, Lq., Chen, Xl., Wang, Q. et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin 28, 879–887 (2007). https://doi.org/10.1111/j.1745-7254.2007.00571.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00571.x
Keywords
This article is cited by
-
Study on the effects of the different polar group of EPA-enriched phospholipids on the proliferation and apoptosis in 95D cells
Marine Life Science & Technology (2021)
-
The study of effect and mechanism of 630-nm laser on human lung adenocarcinoma cell xenograft model in nude mice mediated by hematoporphyrin derivatives
Lasers in Medical Science (2020)
-
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
Medical Oncology (2017)
-
Vinegar decreases blood pressure by down-regulating AT1R expression via the AMPK/PGC-1α/PPARγ pathway in spontaneously hypertensive rats
European Journal of Nutrition (2016)
-
Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET
Tumor Biology (2015)